Department of Civil Engineering, University of Granada, Granada 18071, Spain; Institute of Water Research, University of Granada, Granada 18071, Spain.
Department of Chemical Engineering, University of Granada, Granada 18071, Spain.
Sci Total Environ. 2020 Mar 15;708:135104. doi: 10.1016/j.scitotenv.2019.135104. Epub 2019 Nov 16.
This research was performed to assess the production of reclaimed water from urban wastewater in membrane bioreactor - advanced oxidation process (MBR-AOP) and moving bed biofilm reactor - membrane bioreactor - advanced oxidation process (MBBR-MBR-AOP) combined treatments to study the effect of biofilm incorporation. Both combined treatments were operated at the same conditions (10 h of hydraulic retention time, 6500 mg/L of mixed liquor suspended solids and 25 mg/L of hydrogen peroxide dosage over 15 min). Additionally, the removal capacity of some pharmaceuticals (carbamazepine, ciprofloxacin and ibuprofen) and their impact on the kinetic behaviour of the biomass in both systems were evaluated. From the results, it was found a membrane-based bioreactor can achieve both wastewater secondary treatment and pre-treatment for advanced oxidation process, so both MBR-AOP and MBBR-MBR-AOP treatments have a great potential to produce high quality reclaimed water (biological oxygen demand <0.5 mgO/L, suspended solids <1 mg/L, turbidity <1 NTU and no presence of E. coli), according to European Commission proposal 2018/0169/COD. The addition of carriers improved the biodegradation of the most persistent pharmaceuticals in the biological treatment (from 69.20 ± 1.54% to 75.14 ± 2.71% for carbamazepine and from 60.41 ± 2.16 to 63.14 ± 2.70% for ciprofloxacin). It had, as a consequence, the MBBR-MBR-AOP system showing a complete degradation of pharmaceuticals after 5 min AOP treatment compared to the MBR-AOP system. The loss of biomass in the MBR-AOP (from 5233.45 to 4451.92 mg/L) and the increase of the substrate degradation rate for organic matter in both treatments (from 37.27 to 41.42 and from 30.25 to 33.19 mgO/(L·h) in MBR-AOP and MBBR-MBR-AOP, respectively) are some of the consequences of pharmaceuticals in urban wastewater.
本研究旨在评估膜生物反应器-高级氧化工艺（MBR-AOP）和移动床生物膜反应器-膜生物反应器-高级氧化工艺（MBBR-MBR-AOP）组合处理中从城市废水中生产再生水的情况，以研究生物膜的影响。这两种组合处理都在相同的条件下运行（水力停留时间为 10 小时，混合液悬浮固体浓度为 6500mg/L，过氧化氢剂量为 25mg/L，持续 15 分钟）。此外，还评估了一些药物（卡马西平、环丙沙星和布洛芬）的去除能力及其对两种系统中生物量动力学行为的影响。结果表明，基于膜的生物反应器可以实现废水的二级处理和高级氧化过程的预处理，因此 MBR-AOP 和 MBBR-MBR-AOP 处理都具有生产高质量再生水的巨大潜力（生物需氧量<0.5mgO/L、悬浮物<1mg/L、浊度<1NTU 且不存在大肠杆菌），符合欧盟委员会 2018/0169/COD 提案。载体的添加提高了生物处理中最持久药物的可生物降解性（卡马西平从 69.20±1.54%提高到 75.14±2.71%，环丙沙星从 60.41±2.16%提高到 63.14±2.70%）。因此，与 MBR-AOP 系统相比，MBBR-MBR-AOP 系统在经过 5 分钟的 AOP 处理后，药物完全降解。MBR-AOP 中生物量的损失（从 5233.45 到 4451.92mg/L）和两种处理中有机物底物降解率的提高（从 37.27 到 41.42 和从 30.25 到 33.19mgO/（L·h），分别在 MBR-AOP 和 MBBR-MBR-AOP 中）都是城市废水中药物的一些后果。
